iiinova — where your digital self keeps evolving

Reposted by Axel Merseburger

Medthority @medthority.bsky.social · 12/06/2025

Can investigational treatments address unmet needs in mCRPC, and what are the barriers to uptake of clinical practice guidelines? Get answers with expert opinions from @axelmerseburger.bsky.social and @neerajagarwal.bsky.social on the latest in mCRPC management #MedSky #MedEd ow.ly/xIiE50W8qk2

022

Reposted by Axel Merseburger

Medthority @medthority.bsky.social · 02/06/2025

Listen to @sfreedlandmd.bsky.social and @axelmerseburger.bsky.social discuss personalised medicine, molecular testing, and improving patient quality of life in #mCRPC with NEW podcast episodes #ProstateCancer #Oncology #Podcast #MedSky #MedicalEducation #MedEd ow.ly/pQWx50W2IAp

042

Reposted by Axel Merseburger

Yüksel Ürün @yukselurun.bsky.social · 06/04/2025

Can a shingles vaccine protect the brain? Zoster vaccination linked to a 20% lower risk of dementia over 7 years. @nature.com rdcu.be/egydp

021

Reposted by Axel Merseburger

Martin Schostak MD, PhD @martin-schostak.bsky.social · 24/03/2025

Proud to be one of the investigators: #MicroUS noninferior to MRI fusion for csPCa (46.1% vs 42.6%)! No MRI, slightly better results. 802 pts, 8 countries. Just presented #EAU25 and published in #JAMA. #ProstateCancer #biopsy @axelmerseburger.bsky.social

371

Reposted by Axel Merseburger

Martin Schostak MD, PhD @martin-schostak.bsky.social · 24/03/2025

LATP hits harder: +5.7% GG≥2 vs TRUS (p=0.031)! Fewer infections, slightly more pain & embarrassment. No abx needed. Costlier, slower—but sharper. #TRANSLATEtrial #ProstateCancer #LATP #TRUS #EAU25 #LancetOncology @axelmerseburger.bsky.social

041

Reposted by Axel Merseburger

The Advanced Prostate Cancer Consensus Conference @apccc.bsky.social · 31/03/2025

FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication www.fda.gov/drugs/resour... FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer who have been treated with ARPI

fda.gov

FDA expands Pluvicto’s prostate cancer indication

On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto).

044

Reposted by Axel Merseburger

Martin Schostak MD, PhD @martin-schostak.bsky.social · 08/02/2025

🚀 Excited for #ASCOGU25! Looking forward to groundbreaking insights and game-changers once again! 🔬 Can't wait to see what’s ahead. 🎯 Stay tuned! #UroOncology #GameChanger @axelmerseburger.bsky.social

031

Axel Merseburger @axelmerseburger.bsky.social · 05/02/2025

🚀 Who are the top oncologists leading the digital conversation? 📢 Check out this ranking of digital thought leaders in oncology based on their Twitter following! 📊 Notably, female oncologists highlighted in green! 👇 #GU25 #ASCOGU25

020

Reposted by Axel Merseburger

Axel Merseburger @axelmerseburger.bsky.social · 25/01/2025

🎉 Great News! 🎉 I am delighted that we received a total of 4 awards in the renowned Focus Clinic List, thanks to the tremendous support from the entire team at the Urology Clinic! Our recognitions include: - #BladderCancer - #ProstateCancer - #KidneyCancer - #Oncology

021

Axel Merseburger @axelmerseburger.bsky.social · 25/01/2025

021

Reposted by Axel Merseburger

Yüksel Ürün @yukselurun.bsky.social · 30/12/2024

Immunotherapy shows sex bias—men respond better; women face more severe AEs. Understanding sex hormones, chromosomes, and epigenetics in immunity could lead to tailored immuno-oncology strategies. #Cancer #Immunotherapy #Oncology @oncoalert.bsky.social rdcu.be/d49Mq

0259

Reposted by Axel Merseburger

Martin Schostak MD, PhD @martin-schostak.bsky.social · 19/12/2024

Ich verlasse nicht nur die Uni #Magdeburg, sondern auch #X – weil es jetzt einfach reicht! Ab sofort findet ihr mich hier und unter logicuro.com @axelmerseburger.bsky.social

051